The FDA has granted breakthrough therapy designation to the ROS1 inhibitor taletrectinib for the treatment of patients with advanced or...
NSCLC
On August 11, 2022, the FDA gave the green light for accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic...
Lung cancer is a malignant lung tumor. It is considered the most common type of cancer in men and the third...
In September, the FDA approved 2 new medications in the oncology & hematology category. Pralsetinib was approved for adult patients...
